Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fulcrum Therapeutics Inc FULC

Healthcare
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.


NDAQ:FULC - Post by User

Fulcrum Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(229)
•••
Post by whytestockson Sep 12, 2024 5:15pm
32 Views
Post# 36221175

Fulcrum Therapeutics stock tanks after Phase 3 trial failure

Fulcrum Therapeutics stock tanks after Phase 3 trial failure
JUST IN: $FULC Fulcrum Therapeutics stock tanks after Phase 3 trial failure of muscular dystrophy drug2024-09-12 10:31:01 ET Fulcrum Therapeutics Inc. (NASDAQ: FULC) saw its stock plunge 65% on Thursday after announcing that its late-stage trial for losmapimod, a treatment for facioscapulohumeral muscular dystrophy (FSHD), failed to meet its primary endpoint. This significant setbac...FULC - Fulcrum Therapeutics stock tanks after Phase 3 trial failure of muscular dystrophy drug

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities